Ross Procedure Emerges as a New Gold Standard for Young Patients Requiring Aortic Valve Replacement<\/p>\n
Source: Journal of the American College of Cardiology, published online June 23, 2026.<\/p>\n
\u2022\u2060 \u2060In a high-volume Ross center (455 patients), 12-year survival matched that of the age-matched general population.
\n\u2022\u2060 \u2060Excellent durability:
\n* Aortic valve reintervention: 1.1% at 12 years.
\n* Any cardiac reintervention: 3.5%.
\n\u2022\u2060 \u2060Outstanding hemodynamic performance:
\n* Mean aortic valve gradient: 4 mmHg at 12 years.
\n* No prosthesis\u2013patient mismatch.
\n\u2022\u2060 \u2060Permanent pacemaker implantation: only 0.8%.
\n\u2022\u2060 \u2060Outcomes were similar in patients >50 and <50 years.
\n\u2022\u2060 \u2060The Ross procedure replaces the diseased aortic valve with the patient\u2019s own pulmonary valve (living autograft), providing near-normal valve function, preserving exercise capacity, avoiding lifelong anticoagulation in most patients, and potentially restoring normal life expectancy.
\n\u2022\u2060 \u2060In carefully selected patients, Ross may provide superior long-term survival and valve performance compared with conventional prosthetic valve replacement.
\n\u2022\u2060 \u2060Key limitation: Excellent outcomes depend on careful patient selection and experienced, high-volume Ross centers; broader adoption requires standardized quality metrics and surgical expertise.
\n\u2022\u2060 \u2060Despite accumulating evidence, the Ross procedure remains a Class IIb recommendation in the 2020 ACC\/AHA Valvular Heart Disease Guideline, although many experts anticipate stronger recommendations in future guideline updates.<\/p>\n
Take-home message: For appropriately selected patients\u2014particularly younger adults treated at experienced Ross centers\u2014the Ross procedure is increasingly emerging as the benchmark surgical option for aortic valve replacement.<\/p>\n